

OCT
25
1994

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

[Handwritten signature]

In re the Application of David Porubek, Anil M. Kumar
and Charles R. Bredl

Group Art Unit: to be assigned

Application No.: to be assigned

Examiner: to be assigned

Filed: October 25, 1994

Docket No.: 0204

For: COMPOUNDS HAVING SELECTIVE HYDROLYTIC POTENTIALS

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- X 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).
- b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual

**DEPOSIT ACCOUNT USE
AUTHORIZATION**

Please grant any extension necessary for entry.

Charge any fee due to our

DEPOSIT ACCOUNT NO. 03-1182.

designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).

- c. Please debit or credit the \$210.00 fee to Account No. 03-1182 under 37 C.F.R. 1.17(p), or as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered. Please debit or credit the \$130.00 fee to Account No. 03-1182 under 37 C.F.R. 1.17(i)(1), or as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).
- b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).
- X 4. The relevance of the enclosed references is discussed in the specification with the exception of Allevi *et al.*, which provides technical background.

Respectfully submitted,



Stephen Faciszewski
Attorney for Applicants
Registration No. 36,131

Date: October 25, 1994

CELL THERAPEUTICS, INC.
201 Elliott Avenue West, Suite 400
Seattle, Washington 98119
Telephone: (206) 282-7100
Fax Number: (206) 284-6206
10/94